Estradiol valerate | Altadiol | Deladiol | Delestrogen | Estrava | Progynova | Valergen | oestradiol valerate | CAS#979-32-8

MedKoo Cat#: 314221 | Name: Estradiol valerate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Estradiol valerate is a synthetic ester, specifically the 17-pentanoyl ester, of the natural estrogen, 17β-estradiol. It was introduced in the 1950s, and along with estradiol benzoate and estradiol cypionate, has since become one of the most widely used esters of estradiol. (Source: http://en.wikipedia.org/wiki/Estradiol_valerate).

Chemical Structure

Estradiol valerate

CAS#979-32-8 (valerate)

Theoretical Analysis

MedKoo Cat#: 314221

Name: Estradiol valerate

CAS#: 979-32-8 (valerate)

Chemical Formula: C23H32O3

Exact Mass: 356.2351

Molecular Weight: 356.50

Elemental Analysis: C, 77.49; H, 9.05; O, 13.46

Price and Availability

Size	Price	Availability
100mg	USD 250.00	2 weeks
250mg	USD 450.00	2 weeks
500mg	USD 750.00	2 weeks
1g	USD 1,150.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

50-28-2 50-50-0 (benzoate) 313-06-4 (cypionate) 113-38-2 (dipropionate) 172377-52-5 (sulfamate) 979-32-8 (valerate) 57-63-6 (ethinyl) 3571-53-7 (undecylate)

Synonym

Altadiol; Deladiol; Delestrogen; Estraval; Progynova; Valergen; oestradiol valerate; 17Estradiol17valerate pentanoate destra135(10)trine3ol17yle

IUPAC/Chemical Name

(17β)-3-hydroxyestra-1,3,5(10)-trien-17-yl valerate

InChi Key

RSEPBGGWRJCQGY-RBRWEJTLSA-N

InChi Code

InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1

SMILES Code

CCCCC(O[C@H]1CC[C@@]2([H])[C@]3([H])CCC4=C(C=CC(O)=C4)[C@@]3([H])CC[C@]12C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 356.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wellington K, Perry CM. Estradiol valerate/dienogest. Drugs. 2002;62(3):491-504; discussion 505-6. doi: 10.2165/00003495-200262030-00006. PMID: 11827562. 2: Whalen KL, Rose R. Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother. 2011 Oct;45(10):1256-61. doi: 10.1345/aph.1Q216. Epub 2011 Sep 13. PMID: 21917554. 3: Hoy SM, Scott LJ. Estradiol valerate/dienogest: in oral contraception. Drugs. 2009 Aug 20;69(12):1635-46. doi: 10.2165/11202820-000000000-00000. PMID: 19678714. 4: Borgelt LM, Martell CW. Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther. 2012 Jan;34(1):37-55. doi: 10.1016/j.clinthera.2011.11.006. Epub 2011 Dec 14. PMID: 22169052. 5: Haupt C, Henke M, Kutschmar A, Hauser B, Baldinger S, Saenz SR, Schreiber G. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women. Cochrane Database Syst Rev. 2020 Nov 28;11(11):CD013138. doi: 10.1002/14651858.CD013138.pub2. PMID: 33251587; PMCID: PMC8078580. 6: Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric. 2003 Aug;6 Suppl 2:17-23. PMID: 14669840. 7: Graziottin A. Contraception containing estradiol valerate and dienogest-- advantages, adherence and user satisfaction. Minerva Ginecol. 2014 Oct;66(5):479-95. PMID: 25245997. 8: Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother. 2010 May;11(7):1147-57. doi: 10.1517/14656561003724713. PMID: 20367275. 9: Haverinen A, Luiro K, Kangasniemi MH, Piltonen TT, Hustad S, Heikinheimo O, Tapanainen JS. Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3008-e3017. doi: 10.1210/clinem/dgac150. PMID: 35279718. 10: Fruzzetti F, Trémollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012 May;28(5):400-8. doi: 10.3109/09513590.2012.662547. Epub 2012 Apr 2. PMID: 22468839; PMCID: PMC3399636. 11: ESTRADIOL valerate. J Am Med Assoc. 1958 Mar 22;166(12):1482. PMID: 13513388. 12: Micks EA, Jensen JT. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv Ther. 2013 Jan;30(1):1-13. doi: 10.1007/s12325-012-0071-3. Epub 2012 Dec 12. PMID: 23239397. 13: Haverinen A, Kangasniemi M, Luiro K, Piltonen T, Heikinheimo O, Tapanainen JS. Ethinyl estradiol vs estradiol valerate in combined oral contraceptives - Effect on glucose tolerance: A randomized, controlled clinical trial. Contraception. 2021 Jan;103(1):53-59. doi: 10.1016/j.contraception.2020.10.014. Epub 2020 Oct 21. PMID: 33098852. 14: Blockeel C. Estradiol valerate pretreatment in GnRH-antagonist cycles. Reprod Biomed Online. 2012 Aug;25(2):223-4. doi: 10.1016/j.rbmo.2012.03.015. Epub 2012 Apr 5. PMID: 22695312. 15: Qian X, Wang J, Cai M, Sun H, Xu H, Wen H, Zhu H. Estradiol Valerate Enhances Cardiac Function via the Nrf2 Signaling Pathway to Protect Against Oxidative Stress by the Nrf2 Signaling Pathway in an Ovariectomized Rat Model. Curr Pharm Des. 2021;27(46):4716-4725. doi: 10.2174/1381612827666210927162612. PMID: 34579626. 16: Vatrasresth J, Suwan A, Panyakhamlerd K. Effects of early estradiol valerate administration on bone turnover markers in surgically induced menopausal women. BMC Womens Health. 2021 Oct 13;21(1):363. doi: 10.1186/s12905-021-01508-w. PMID: 34645447; PMCID: PMC8515676. 17: Wang W, Cui G, Jin B, Wang K, Chen X, Sun Y, Qin L, Bai W. Estradiol Valerate and Remifemin ameliorate ovariectomy-induced decrease in a serotonin dorsal raphe-preoptic hypothalamus pathway in rats. Ann Anat. 2016 Nov;208:31-39. doi: 10.1016/j.aanat.2016.08.001. Epub 2016 Aug 22. PMID: 27562857. 18: Egarter C, Geurts P, Boschitsch E, Speiser P, Huber J. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Acta Obstet Gynecol Scand. 1996 Apr;75(4):386-93. doi: 10.3109/00016349609033337. PMID: 8638462. 19: Quirarte GL, Reid LD, de la Teja IS, Reid ML, Sánchez MA, Díaz-Trujillo A, Aguilar-Vazquez A, Prado-Alcalá RA. Estradiol valerate and alcohol intake: dose- response assessments. BMC Pharmacol. 2007 Mar 4;7:3. doi: 10.1186/1471-2210-7-3. PMID: 17335585; PMCID: PMC1821017. 20: Romano-Torres M, Fernández-Guasti A. Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress. Behav Pharmacol. 2010 Mar;21(2):104-11. doi: 10.1097/FBP.0b013e328337bdfc. PMID: 20168212.